Elicio Therapeutics (ELTX) Change in Account Payables (2020 - 2026)
Elicio Therapeutics posted quarterly Change in Account Payables of -$460000.0 for Q1 2026, down 115.34% year-on-year from $3.0 million in Q1 2025, and down 231.05% on a QoQ basis from $351000.0 in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Change in Account Payables data on file, last reported at -$460000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 115.34% year-over-year to -$460000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.8 million (down 230.46% YoY), and the FY2025 full-year result was -$366000.0, up 89.01% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$460000.0, down from $351000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.1 million in Q2 2022 and bottomed at -$3.5 million in Q3 2025.
- The 5-year median for Change in Account Payables is -$172000.0 (2025), against an average of -$177000.0.
- Peak annual rise in Change in Account Payables reached 554.23% in 2024, while the deepest fall reached 2265.0% in 2024.
- A 5-year view of Change in Account Payables shows it stood at -$282000.0 in 2022, then jumped by 85.82% to -$40000.0 in 2023, then tumbled by 2265.0% to -$946000.0 in 2024, then soared by 137.1% to $351000.0 in 2025, then plunged by 231.05% to -$460000.0 in 2026.
- The last three Change in Account Payables figures came in at -$460000.0 (Q1 2026), $351000.0 (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -3.26 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 35.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -460,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -460,000.00 |
| Mar 31, 2026 | -460,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | -3.54 Mn |
| Sep 30, 2025 | -3.54 Mn |
| Jun 30, 2025 | -172,000.00 |
| Jun 30, 2025 | -172,000.00 |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | -946,000.00 |
| Dec 31, 2024 | -946,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -50,000.00 |
| Mar 31, 2024 | -3.26 Mn |
| Mar 31, 2024 | -3.26 Mn |
| Dec 31, 2023 | -40,000.00 |
| Dec 31, 2023 | -40,000.00 |
| Sep 30, 2023 | 142,000.00 |
| Sep 30, 2023 | 142,000.00 |
| Jun 30, 2023 | -1.46 Mn |
| Jun 30, 2023 | -1.46 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | -282,000.00 |
| Dec 31, 2022 | -282,000.00 |
| Sep 30, 2022 | -352,000.00 |
| Sep 30, 2022 | -352,000.00 |
| Jun 30, 2022 | 3.08 Mn |
| Jun 30, 2022 | 3.08 Mn |
| Mar 31, 2022 | -1.32 Mn |
| Mar 31, 2022 | -1.32 Mn |
| Dec 31, 2021 | -2.94 Mn |
| Dec 31, 2021 | -2.94 Mn |
| Sep 30, 2021 | -1.66 Mn |
| Sep 30, 2021 | -1.66 Mn |
| Jun 30, 2021 | 2.62 Mn |
| Jun 30, 2021 | 2.62 Mn |
| Mar 31, 2021 | 1.11 Mn |
| Mar 31, 2021 | 1.11 Mn |
| Dec 31, 2020 | 923,000.00 |
| Dec 31, 2020 | 923,000.00 |
| Sep 30, 2020 | -12.35 Mn |
| Sep 30, 2020 | -12.35 Mn |
| Jun 30, 2020 | 4.37 Mn |
| Jun 30, 2020 | 4.37 Mn |
| Mar 31, 2020 | 1.45 Mn |
| Mar 31, 2020 | 1.45 Mn |